| Abstract: | To improve the bioimaging signal‐to‐noise ratio (SNR), long‐term imaging capability, and decrease the potential biotoxicity, an in vivo cross‐linking strategy was developed by using sub‐10 nm, glutathione‐modified, lanthanide nanoprobes. After administration, the nanoprobes cross‐link in response to reactive oxygen species (ROS) at the inflamed area and enable the quick imaging of ROS in the second near‐infrared (NIR‐II) window. These nanoprobes could be rapidly excreted due to their ultra‐small size. This strategy may also be applied to other ultra‐small contrast agents for the precise bioimaging by in situ lesion cross‐linking. |
